

2012-1431

UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT

OSI PHARMACEUTICALS, INC.,
PFIZER, INC., and GENENTECH INC.,

Plaintiffs-Appellees,

v.

MYLAN PHARMACEUTICALS INC.,

Defendant-Appellant.

Appeal from the United States District Court for the District of
Delaware in case no. 09-CV-0185, Judge Sue L. Robinson.

**REPLY BRIEF OF DEFENDANT-APPELLANT
MYLAN PHARMACEUTICALS INC.**

James H. Wallace, Jr.
Mark A. Pacella
Gregory R. Lyons
Adrienne G. Johnson
WILEY REIN LLP
1776 K Street NW
Washington, DC 20006
(202) 719-7000
*Attorneys for Defendant-
Appellant Mylan Pharmaceuticals
Inc.*

CERTIFICATE OF INTEREST

Pursuant to Federal Circuit Rule 47.4, counsel for the Defendant-Appellant

Mylan Pharmaceuticals Inc. certifies the following:

1. The full name of every party or amicus represented by me is:

Mylan Pharmaceuticals Inc.

2. The name of the real party in interest (if the party named in the caption is not the real party in interest) represented by me is:

Mylan Pharmaceuticals Inc.

3. All parent corporations and any publicly held companies that own 10 percent or more of the stock of the party or amicus curiae represented by me are:

Mylan Inc.

4. The names of all law firms and the partners or associates that appeared for the party or amicus now represented by me in the trial court or agency or are expected to appear in this court are:

Jack C. Phillips, Jr.
Megan C. Haney
Brian E. Farnan
Phillips, Goldman & Spence, P. A.
1200 N. Broom Street
Wilmington, DE 19806

James H. Wallace, Jr.
Mark A. Pacella
Gregory R. Lyons
Robert J. Scheffel
Brian Pandya
Matthew J. Dowd
Karin A. Hessler
Adrienne G. Johnson
WILEY REIN LLP
1776 K Street NW
Washington, DC 20006

Date: October 25, 2012

/s/Mark A. Pacella
Signature of counsel

Mark A. Pacella
Printed name of counsel

TABLE OF CONTENTS

	Page
I. INTRODUCTION	1
II. USE OF ERLOTINIB TO TREAT NSCLC AS CLAIMED IN THE '221 PATENT WAS ANTICIPATED	4
A. The '498 Patent's Express Disclosure Of Erlotinib Within A Discrete Set Of Compounds For Treating A Discrete Set Of Disease Anticipated Claim 53 Of The '221 Patent	4
B. The Cold Spring Harbor Abstract Anticipated Claim 53.....	9
III. USING ERLOTINIB TO TREAT NSCLC AS CLAIMED IN THE '221 PATENT WAS OBVIOUS	10
A. By 1999, Erlotinib's Promise As A NSCLC Treatment Was Readily Apparent.....	11
B. Plaintiffs' No "Reasonable Expectation Of Success" Argument Erroneously Defines "Success" As Proof Of Actual Success And FDA Approval	13
C. No Secondary Considerations Supported Non-Obviousness.....	15
IV. THE ERLOTINIB COMPOUND AS CLAIMED IN THE RE '065 PATENT WAS OBVIOUS	16
A. The District Court's Rigid Focus On Biological Data As A Prerequisite To Obviousness Contravenes Binding Precedent.....	17
B. Contrary To Plaintiffs' Contention, Mylan's Obviousness Case Was Not Based On Hindsight	21
C. The Prior Art Did Not Teach Away From Using The Ethynyl Group At The 3'-Position.....	23
D. The District Court Found No Unexpected Results Or Secondary Considerations Supporting Non-Obviousness	26
V. CONCLUSION.....	29

TABLE OF AUTHORITIES

	Page(s)
CASES	
<i>In re Arkley</i> , 455 F.2d 586 (C.C.P.A. 1972)	5
<i>Akzo N.V. v. United States International Trade Commission</i> , 808 F.2d 1471 (Fed. Cir. 1986)	5
<i>In re Blondel</i> , 499 F.2d 1311 (C.C.P.A. 1974)	26
<i>Celeritas Technologies, Ltd. v. Rockwell International Corp.</i> , 150 F.3d 1354 (Fed. Cir. 1998)	9
<i>In re Cyclobenzaprine Hydrochloride Extended-Release Patent Litigation</i> , 676 F.3d 1063 (Fed. Cir. 2012)	16
<i>Daiichi Sankyo Co. v. Matrix Labs, Ltd.</i> , 619 F.3d 1346 (Fed. Cir. 2010)	18
<i>Datascope Corp. v. SMEC, Inc.</i> , 776 F.2d 320 (Fed. Cir. 1985)	17
<i>In re Deters</i> , 515 F.2d 1152 (C.C.P.A. 1975)	27
<i>Eisai Co. v. Dr. Reddy’s Laboratories, Ltd.</i> , 533 F.3d 1353 (Fed. Cir. 2008)	19
<i>Eli Lilly & Co. v. Teva Pharmaceuticals USA, Inc.</i> , 619 F.3d 1329 (Fed. Cir. 2010)	14
<i>Eli Lilly & Co. v. Zeith Goldline Pharmaceuticals, Inc.</i> 471 F.3d 1369 (Fed. Cir. 2006)	16
<i>Ferring B.V. v. Barr Laboratories, Inc.</i> , 437 F.3d 1181 (Fed. Cir. 2006)	27
<i>In re Gleave</i> , 560 F.3d 1331 (Fed. Cir. 2009)	6

Graham v. John Deere Co.,
 383 U.S. 1 (1966).....16, 26

In re Huang,
 100 F.3d 135 (Fed. Cir. 1996) (*See Mylan Br. 66-67.*)28

Ex Parte Humber,
 217 U.S.P.Q. 265 (B.P.A.I. 1981)26

Impax Laboratories, Inc. v. Aventis Pharmaceuticals Inc.,
 545 F.3d 1312 (Fed. Cir. 2008)9

Kinetic Concepts, Inc. v. Smith & Nephew, Inc.,
 688 F.3d 1342 (Fed. Cir. 2012)11

Koito Manufacturing Co. v. Turn-Key-Tech, LLC,
 381 F.3d 1142 (Fed. Cir. 2004)10

KSR International Co. v. Teleflex Inc.,
 550 U.S. 398 (2007).....17, 18, 20

In re Kubin,
 561 F.3d 1351 (Fed. Cir. 2009)13

Metabolite Laboratories Inc. v. Laboratory Corp.,
 370 F.3d 1354 (Fed. Cir. 2004)6

Motorola, Inc. v. Interdigital Technology Corp.,
 121 F.3d 1461 (Fed. Cir. 1997)10

Otsuka Pharmaceutical Co. v. Sandoz, Inc.,
 678 F.3d 1280 (Fed. Cir. 2012)8, 19

In re Payne,
 606 F.2d 303 (C.C.P.A. 1979)26

Perricone v. Medicis Pharmaceutical Corp.,
 432 F.3d 13686

Purdue Pharma Products L.P. v. Par Pharmaceutical, Inc.,
 377 F. App'x 978 (Fed. Cir. 2010)28

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.